Assessment of circulating tumor cells and serum markers for progression-free survival prediction in metastatic breast cancer: a prospective observational study.
about
Circulating Tumor Cells: A Window Into Tumor Development and Therapeutic EffectivenessClinical application of circulating tumor cells in breast cancer: overview of the current interventional trialsCirculating tumor cells in breast cancer.Circulating tumor cells: from bench to bedsideAssociation of CA 15-3 and CEA with clinicopathological parameters in patients with metastatic breast cancer.Markers for the identification of late breast cancer recurrence.New Approach for Interpreting Changes in Circulating Tumour Cells (CTC) for Evaluation of Treatment Effect in Metastatic Breast Cancer.Different Levels of CEA, CA153 and CA125 in Milk and Benign and Malignant Nipple Discharge.Serum HER2 extra-cellular domain, S100ß and CA 15-3 levels are independent prognostic factors in metastatic breast cancer patientsClinical relevance of circulating CK-19mRNA-positive tumour cells before front-line treatment in patients with metastatic breast cancer.Combination Twist1 and CA15-3 in axillary lymph nodes for breast cancer prognosis.Circulating tumor cell status monitors the treatment responses in breast cancer patients: a meta-analysis.Progress in using circulating tumor cell information to improve metastatic breast cancer therapyEstablishment and validation of circulating tumor cell-based prognostic nomograms in first-line metastatic breast cancer patients.A randomized phase II trial investigating the effect of platelet function inhibition on circulating tumor cells in patients with metastatic breast cancerPrognostic value of pretreatment serum lactate dehydrogenase level in patients with solid tumors: a systematic review and meta-analysis.Controversies in circulating tumor cell count during therapy.Circulating tumor DNA for triple-negative breast cancer diagnosis and treatment decisions.MRP1 expression in CTCs confers resistance to irinotecan-based chemotherapy in metastatic colorectal cancer.Serum CA125 is a predictive marker for breast cancer outcomes and correlates with molecular subtypes.Metastasis and Circulating Tumor Cells.Clinicopathological and prognostic significance of circulating tumor cells in patients with lung cancer: a meta-analysisElevation of serum CEA and CA15-3 levels during antitumor therapy predicts poor therapeutic response in advanced breast cancer patients.Circulating tumor cells and brain metastasis outcome in patients with HER2-positive breast cancer: the LANDSCAPE trial.Glypican-3 and KRT19 are markers associating with metastasis and poor prognosis of pancreatic ductal adenocarcinoma.
P2860
Q26827815-ECF9D389-A92F-4938-BCE2-6D69D2FFECABQ26827936-FCABB4FC-04CE-4576-B044-6AFDAB6549B9Q34077349-04FD97C3-4657-4F18-B5F7-4A2FD3C6AF64Q34307782-C66B3C8F-A2C8-4242-89D9-EF3984231E10Q34607218-3777F1BF-F25B-4D1C-83C7-7693704004CEQ35018949-F69841FC-00C3-4A73-9476-0435FC524C8BQ35028760-089FE83B-CCDF-4F39-AF2D-1D967CC96D5EQ36057627-B34DAFB4-0015-4A51-A7AC-31536BC4ECABQ36069770-E127858E-C20A-496A-A8B7-4D9A5DB0F06EQ36072794-8751E905-6A97-4745-96EF-8A916EBDD7CFQ36256977-9F328228-4FC7-47F6-81A2-48D4660B0FB1Q36321612-E419DAA4-BE34-4C33-8B73-A3DC5F625459Q36752761-BA2F52E0-0697-4061-A0A5-E21BE8D9359FQ36869787-89902379-C60D-4C53-A450-F005ACD8D693Q37630295-CBAEE513-94A6-42CC-87C7-E50619614E2FQ37744341-7C7372E3-38B7-479F-BFE5-9A647459004CQ38115624-6E2CD2D0-E347-4A11-9C41-F33991EF34CFQ38633504-9974BC3F-F093-49ED-A870-141BEA421FA2Q40868446-63ECF8AA-4DEB-4C8F-B3D1-8C4DAF94D07FQ41858523-CBB81440-C9B0-4480-A2C6-A7064560B931Q41872799-47D26845-A34E-480C-9E4B-6590F9591A94Q42365353-68119EF0-3A45-40DF-8E7A-9537A6F8CFF8Q47552039-88A27D90-5357-48CF-86CB-51F0FCC62890Q49061268-059EB426-2A07-4E48-9D96-AB91C68BDCF4Q51445413-6812A16C-887A-4F51-A818-372873BA357E
P2860
Assessment of circulating tumor cells and serum markers for progression-free survival prediction in metastatic breast cancer: a prospective observational study.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Assessment of circulating tumo ...... ospective observational study.
@ast
Assessment of circulating tumo ...... ospective observational study.
@en
type
label
Assessment of circulating tumo ...... ospective observational study.
@ast
Assessment of circulating tumo ...... ospective observational study.
@en
prefLabel
Assessment of circulating tumo ...... ospective observational study.
@ast
Assessment of circulating tumo ...... ospective observational study.
@en
P2093
P2860
P50
P356
P1476
Assessment of circulating tumo ...... ospective observational study.
@en
P2093
Claire Mathiot
David Hajage
Emilie Rolland
Etienne Brain
Jean-Yves Pierga
Mario Campone
Philippe Beuzeboc
Suzette Delaloge
Thomas Bachelot
P2860
P2888
P356
10.1186/BCR3114
P577
2012-02-13T00:00:00Z
P5875
P6179
1039874354